Financial Performance - Operating revenue rose by 44.13% to CNY 74,419,029.40 year-on-year[4] - Net profit attributable to shareholders increased by 37.27% to CNY 12,039,643.64 compared to the same period last year[4] - Basic earnings per share improved by 25.00% to CNY 0.10 per share[4] - Total profit increased by 42.47% to ¥15,502,789.44 from ¥10,881,453.60, mainly due to increased service income and investment returns[12] - Net profit increased by 35.64% to ¥11,895,439.90 from ¥8,770,089.85, attributed to higher service income and investment returns[12] - The company reported a total comprehensive income of 11,373,658.31 for Q1 2019, compared to 8,312,664.70 in Q1 2018, an increase of 37.8%[21] - The company’s total comprehensive income for Q1 2019 was CNY 7.71 million, compared to CNY 3.14 million in Q1 2018, reflecting a strong performance[24] Cash Flow - Net cash flow from operating activities surged by 132.02% to CNY 16,246,365.85 year-to-date[4] - The net cash flow from operating activities for Q1 2019 was RMB 13,141,363.53, a significant increase of 153.5% compared to RMB 5,194,914.96 in Q1 2018[28] - Cash flow from operating activities increased to CNY 16.25 million in Q1 2019, compared to CNY 7.00 million in Q1 2018, marking a 132.5% rise[26] - The cash flow from operating activities showed a strong performance, contributing positively to the overall financial health of the company[28] Assets and Liabilities - Total assets increased by 3.69% to CNY 1,183,561,255.07 compared to the end of the previous year[4] - Total liabilities increased to CNY 553,426,160.01, up from CNY 489,888,909.10, which is a growth of around 12.9%[17] - Current liabilities rose to CNY 472,432,062.72 from CNY 409,192,384.01, indicating an increase of approximately 15.4%[16] - Non-current assets totaled CNY 469,407,405.67, compared to CNY 451,509,885.16, reflecting an increase of about 4.0%[16] - The company reported a total asset value of ¥1,141,409,701.02, indicating a strong asset base[33] Shareholder Information - The total number of shareholders at the end of the reporting period was 7,440[7] - Major shareholder Feng Yuxia holds 28.44% of the shares, with 16,189,966 shares pledged[7] Investment and Income - Investment income surged by 428.51% to ¥6,155,611.39 from ¥1,164,710.96, driven by increased returns from financial products[11] - The company is focusing on expanding its investment activities, as evidenced by the significant increase in cash inflow from investments[29] Expenses - Research and development expenses for Q1 2019 were 7,383,085.52, up from 5,734,005.24 in Q1 2018, marking a 29.0% increase[20] - The company incurred research and development expenses of CNY 2.28 million in Q1 2019, slightly up from CNY 2.23 million in Q1 2018[23] Tax and Subsidies - The company reported government subsidies recognized in the current period amounting to CNY 2,589,676.25[5] - The company reported a 49.41% decrease in taxes payable to ¥4,813,238.55 from ¥9,513,495.30, as initial tax payments were made[10] Financial Standards - The company implemented new financial instrument standards starting January 1, 2019, affecting the presentation of financial assets[39] - The cumulative impact of the new standards was adjusted in the financial statements for the year 2019[39] - The company did not retrospectively adjust comparative financial statements under the new financial instrument standards[39]
昭衍新药(603127) - 2019 Q1 - 季度财报